[ad_1]
Eli Lilly’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to a surge in demand. Whether there will be enough of the drug is a different question.
Both Lilly and its competitor, Denmark’s Novo Nordisk, which makes Ozempic and its sister drug Wegovy, are struggling to meet skyrocketing demand for their medications. There is no quick fix for that given the complexity of building out manufacturing capacity for the injections. Both companies are investing billions of dollars a year to try to catch up.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
[ad_2]
Source link
24World Media does not take any responsibility of the information you see on this page. The content this page contains is from independent third-party content provider. If you have any concerns regarding the content, please free to write us here: contact@24worldmedia.com
Large part of Lynn Woods remains closed
Swampscott water tests lead-free – Itemlive
Mother needs help providing the Christmas experience
A cheerful fundraiser for Saugus team
Carl Daniel Reiter – The Suffolk Times
Joan Ann (Woessner) Polywoda – The Suffolk Times
Thomas L. Lewick – The Suffolk Times
Jeanette Howard – The Suffolk Times
Nina Mazzaferro – The Suffolk Times
Lynn mayor announces re-election bid
BARRETT: They ate plenty – Itemlive
Brooke Moloney, the Minutewoman – Itemlive